Is Morgan Stanley Positive On Shares of ViewRay (VRAY)?

ViewRay, Inc. (NASDAQ:VRAY) Logo

Why Has Morgan Stanley Given ViewRay (VRAY) a $7 Price Target

Morgan Stanley has just issued a Equal-Weight rating for ViewRay (VRAY) shares. The firm has started coverage on shares of VRAY in a research report made public on 11 December. This PT indicates upside of 12.72 % from the last stock close price of ViewRay (VRAY).

ViewRay, Inc. (NASDAQ:VRAY) Ratings Coverage

Among 2 analysts covering ViewRay (VRAY), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ViewRay has $14 highest and $12 lowest target. $13’s average target is 109.34% above currents $6.21 stock price. ViewRay had 2 analyst reports since July 3, 2018 according to SRatingsIntel.

The stock decreased 5.77% or $0.38 during the last trading session, reaching $6.21. About 1.21M shares traded. ViewRay, Inc. (VRAY) has declined 25.28% since December 12, 2017 and is downtrending. It has underperformed by 25.28% the S&P500.

Analysts await ViewRay, Inc. (NASDAQ:VRAY) to report earnings on March, 11. They expect $-0.22 EPS, up 42.11 % or $0.16 from last year’s $-0.38 per share. After $-0.25 actual EPS reported by ViewRay, Inc. for the previous quarter, Wall Street now forecasts -12.00 % EPS growth.

ViewRay, Inc., through its subsidiary, ViewRay Technologies, Inc., designs, makes, and markets radiation therapy systems. The company has market cap of $594.49 million. It offers MRIdian, a radiation therapy solution that enables treatment and real-time imaging of a patientÂ’s anatomy simultaneously. It currently has negative earnings. MRIdian integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered.

More notable recent ViewRay, Inc. (NASDAQ:VRAY) news were published by: which released: “ViewRay Appoints Scott Drake as President, Chief Executive Officer and a Member of the Board of Directors, Shar Matin as Chief Operating Officer, and D. Keith Grossman as a Member of the Board of Directors – PR Newswire” on July 24, 2018, also with their article: “ViewRay Announces Equity Inducement Awards under Nasdaq Listing Rule 5635(c)(4) – PR Newswire” published on September 17, 2018, published: “ViewRay: Initiate Strong Sell On Questionable Backlog, Product Inferiority, And Bankruptcy Concerns – Seeking Alpha” on July 20, 2017. More interesting news about ViewRay, Inc. (NASDAQ:VRAY) were released by: and their article: “ViewRay’s (VRAY) CEO Chris Raanes on Q1 2018 Results – Earnings Call Transcript – Seeking Alpha” published on May 11, 2018 as well as‘s news article titled: “ViewRay’s Clinical Cooperative Think Tank Convenes to Discuss Clinical Experience and Further Trial Development for MRIdian MR-Image Guided Radiotherapy – PR Newswire” with publication date: May 02, 2018.

ViewRay, Inc. (NASDAQ:VRAY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.